-

01:21:48 PM

REGN Stock News

REGN - Regeneron Pharmaceuticals, Inc.

10/03/23 7:00 AM

Nasdaq : REGN

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases

RHEA-AI

positive

09/29/23 8:30 AM

Nasdaq : REGN

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023

RHEA-AI

neutral

09/28/23 4:05 PM

Nasdaq : REGN

conferencesearnings

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open. The Company will host a conference

RHEA-AI

neutral

09/26/23 1:29 AM

Nasdaq : REGN

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, about

RHEA-AI

neutral

09/25/23 8:34 AM

Nasdaq : REGN

acquisition

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on

RHEA-AI

neutral

09/20/23 9:00 AM

Nasdaq : ABCL, REGN

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

AbCellera announced today that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four. “Having successfully delivered on two challenging discovery campaigns under the original agreement, we are excited to expand the scope...

RHEA-AI

neutral

09/08/23 4:46 PM

Nasdaq : REGN

Regeneron Provides Update on Planned Chief Financial Officer Transition

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Robert E.

RHEA-AI

very positive

09/08/23 4:45 PM

Nasdaq : REGN

management

Regeneron Announces Updates to Board of Directors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s Board of

RHEA-AI

positive

08/23/23 4:05 PM

Nasdaq : REGN

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 • Morgan Stanley 21 st Annual Global Healthcare Conference

RHEA-AI

neutral

08/22/23 2:15 PM

Nasdaq : REGN

covid-19

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Biomedical Advanced

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next